Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. He also oversees the Technical Operations, Market Access, Program Management, Clinical Operations and Regulatory Affairs functions.
Mr. Campbell currently serves on the Board of the Association for Regenerative Medicine (ARM) and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals from 2016 until its successful acquisition by Lantheus Holdings in 2020, and the Board of ARYA Sciences Acquisition Corp III, a healthcare focused Special Purpose Acquisition Vehicle formed by Perceptive Advisor.
Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.